151. Differential expression of anterior gradient gene AGR2 in prostate cancer.
- Author
-
Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, and Goodglick L
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma mortality, Adenocarcinoma secondary, Adenocarcinoma surgery, Aged, Gene Expression Profiling methods, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Los Angeles, Lymphatic Metastasis, Male, Middle Aged, Mucoproteins, Neoplasm Recurrence, Local, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Oncogene Proteins, Precancerous Conditions genetics, Precancerous Conditions pathology, Proportional Hazards Models, Prostatectomy, Prostatic Neoplasms genetics, Prostatic Neoplasms mortality, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Proteins genetics, RNA, Messenger analysis, Risk Assessment, Risk Factors, Tissue Array Analysis methods, Treatment Outcome, Adenocarcinoma enzymology, Precancerous Conditions enzymology, Prostatic Neoplasms enzymology, Proteins analysis
- Abstract
Background: The protein AGR2 is a putative member of the protein disulfide isomerase family and was first identified as a homolog of the Xenopus laevis gene XAG-2. AGR2 has been implicated in a number of human cancers. In particular, AGR2 has previously been found to be one of several genes that encode secreted proteins showing increased expression in prostate cancer cells compared to normal prostatic epithelium., Methods: Gene expression levels of AGR2 were examined in prostate cancer cells by microarray analysis. We further examined the relationship of AGR2 protein expression to histopathology and prostate cancer outcome on a population basis using tissue microarray technology., Results: At the RNA and protein level, there was an increase in AGR2 expression in adenocarcinoma of the prostate compared to morphologically normal prostatic glandular epithelium. Using a tissue microarray, this enhanced AGR2 expression was seen as early as premalignant PIN lesions. Interestingly, within adenocarcinoma samples, there was a slight trend toward lower levels of AGR2 with increasing Gleason score. Consistent with this, relatively lower levels of AGR2 were highly predictive of disease recurrence in patients who had originally presented with high-stage primary prostate cancer (P = 0.009)., Conclusions: We have shown for the first time that despite an increase in AGR2 expression in prostate cancer compared to non-malignant cells, relatively lower levels of AGR2 are highly predictive of disease recurrence following radical prostatectomy.
- Published
- 2010
- Full Text
- View/download PDF